logo
The link between malnutrition and type 5 diabetes: What you need to know

The link between malnutrition and type 5 diabetes: What you need to know

Arab Times19-05-2025

NEW YORK, May 19: After years of debate, the International Diabetes Federation (IDF) has officially recognized type 5 diabetes as a distinct diagnosis. This new classification highlights a form of the condition linked to childhood malnutrition, which primarily affects millions of teens and young adults, particularly in regions like Asia and Africa.
Dr. Meredith Hawkins, the founding director of the Global Diabetes Institute at Albert Einstein College of Medicine and co-chair of the IDF working group on type 5 diabetes, noted that type 5 diabetes could also impact certain populations in the United States, including children in foster care or migrants who have faced food insecurity.
Diabetes in all its forms impacts the body's ability to process glucose, a critical energy source for cells. Without proper regulation, glucose accumulates in the bloodstream, potentially causing damage to vital organs, including the eyes, kidneys, nerves, and heart.
Type 1 diabetes occurs when the immune system destroys the insulin-producing cells in the pancreas, resulting in little or no insulin to help cells absorb glucose. In type 2 diabetes, the body either does not use insulin effectively or doesn't produce enough, and obesity is a significant risk factor. However, type 5 diabetes arises from childhood undernutrition, which can impair pancreatic development and reduce insulin production, according to Dr. Hawkins.
Although experts have recognized type 5 diabetes for decades, it was often misclassified as either type 1 or type 2 diabetes. Dr. Hawkins explained that individuals with type 5 diabetes typically require very small amounts of insulin or oral medication, as standard insulin doses can dangerously lower blood sugar and lead to severe complications, even death. She first noticed these treatment failures while treating young patients in Africa years ago.
Currently, the American Diabetes Association (ADA) recognizes type 1, type 2, and gestational diabetes, as well as other types that are caused by specific conditions such as cystic fibrosis, pancreatic disease, organ transplant, steroid therapy, or genetic factors. Other medical organizations acknowledge additional forms of diabetes, such as type 3, which links insulin resistance to Alzheimer's disease, and type 4, which is age-related and found in lean, older adults.
Despite advances in diabetes classification, there is no specific blood test to diagnose type 5 diabetes. Dr. Hawkins explained that the diagnosis is largely based on assessing the clinical picture, particularly the patient's history of childhood malnutrition.
While malnutrition is the primary factor defining type 5 diabetes, Dr. Hawkins believes that awareness of this condition may also benefit individuals in higher-income countries who experience significant weight loss, such as those who undergo bariatric surgery or use GLP-1 medications. Concerns about this issue were raised by colleagues in Japan, who observed young women intentionally starving themselves and displaying a clinical profile similar to that of individuals with type 5 diabetes. However, Dr. Hawkins emphasized that more research is needed to understand whether extreme weight loss can actually lead to type 5 diabetes.
Significant weight loss can reduce muscle mass, which, in turn, affects how the body processes glucose. As skeletal muscle is the body's largest insulin-sensitive tissue and accounts for much of its glucose uptake, losing muscle mass can result in insulin resistance—a condition where cells do not properly respond to insulin, leading to elevated blood sugar levels.
While the American Diabetes Association has not yet classified type 5 diabetes, experts believe that the delay is likely due to the time required for internal review and consensus within the organization. Dr. Hawkins anticipates that the ADA will formally address the condition soon.
Dr. Rozalina McCoy, an associate professor of medicine at the University of Maryland School of Medicine, suggested that there may already be cases of type 5 diabetes in the US that have gone unrecognized by healthcare providers. "It is important to consider this unique type of diabetes and treat it carefully, not only in those who have a childhood history of malnutrition, but also in those who have lost significant weight or are malnourished for other reasons, such as an eating disorder or weight loss treatment, either surgical or medical," McCoy said.
As more attention is brought to type 5 diabetes, healthcare providers are urged to recognize and properly treat this condition, especially for individuals with a history of childhood malnutrition or significant weight loss.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Weight-loss drugs may lower cancer risk in people with diabetes, a study suggests
Weight-loss drugs may lower cancer risk in people with diabetes, a study suggests

Arab Times

time24-05-2025

  • Arab Times

Weight-loss drugs may lower cancer risk in people with diabetes, a study suggests

NEW YORK, May 24, (AP): Excess body weight can raise the risk of certain cancers, leading researchers to wonder whether blockbuster drugs like Wegovy, Ozempic and Zepbound could play a role in cancer prevention. Now, a study of 170,000 patient records suggests there's a slightly lower risk of obesity-related cancers in U.S. adults with diabetes who took these popular medications compared to those who took another class of diabetes drug not associated with weight loss. This type of study can't prove cause and effect, but the findings hint at a connection worth exploring. More than a dozen cancers are associated with obesity. "This is a call to scientists and clinical investigators to do more work in this area to really prove or disprove this,' said Dr. Ernest Hawk of MD Anderson Cancer Center in Houston, who was not involved in the study. The findings were released Thursday by the American Society of Clinical Oncology and will be discussed at its annual meeting in Chicago. The study, funded by the National Institutes of Health, was led by Lucas Mavromatis, a medical student at New York University's Grossman School of Medicine. "Chronic disease and chronic disease prevention are some of my passions,' said Mavromatis, a former research fellow with an NIH training program. GLP-1 receptor agonists are injections used to treat diabetes, and some are also approved to treat obesity. They work by mimicking hormones in the gut and the brain to regulate appetite and feelings of fullness. They don't work for everyone and can produce side effects that include nausea and stomach pain. In the study, researchers analyzed data from 43 U.S. health systems to compare two groups: people with obesity and diabetes who took GLP-1 drugs and other people with the same conditions who took diabetes drugs like sitagliptin. The two groups were equal in size and matched for other characteristics. After four years, those who took GLP-1 drugs had a 7% lower risk of developing an obesity-related cancer and an 8% lower risk of death from any cause compared to those who took the other type of diabetes drug. There were 2,501 new cases of obesity-related cancer in the GLP-1 group compared to 2,671 cases in the other group. The effect was evident in women, but not statistically significant in men. The study couldn't explain that difference, but Mavromatis noted that differences in blood drug concentration, weight loss, metabolism or hormones could be at play.

The link between malnutrition and type 5 diabetes: What you need to know
The link between malnutrition and type 5 diabetes: What you need to know

Arab Times

time19-05-2025

  • Arab Times

The link between malnutrition and type 5 diabetes: What you need to know

NEW YORK, May 19: After years of debate, the International Diabetes Federation (IDF) has officially recognized type 5 diabetes as a distinct diagnosis. This new classification highlights a form of the condition linked to childhood malnutrition, which primarily affects millions of teens and young adults, particularly in regions like Asia and Africa. Dr. Meredith Hawkins, the founding director of the Global Diabetes Institute at Albert Einstein College of Medicine and co-chair of the IDF working group on type 5 diabetes, noted that type 5 diabetes could also impact certain populations in the United States, including children in foster care or migrants who have faced food insecurity. Diabetes in all its forms impacts the body's ability to process glucose, a critical energy source for cells. Without proper regulation, glucose accumulates in the bloodstream, potentially causing damage to vital organs, including the eyes, kidneys, nerves, and heart. Type 1 diabetes occurs when the immune system destroys the insulin-producing cells in the pancreas, resulting in little or no insulin to help cells absorb glucose. In type 2 diabetes, the body either does not use insulin effectively or doesn't produce enough, and obesity is a significant risk factor. However, type 5 diabetes arises from childhood undernutrition, which can impair pancreatic development and reduce insulin production, according to Dr. Hawkins. Although experts have recognized type 5 diabetes for decades, it was often misclassified as either type 1 or type 2 diabetes. Dr. Hawkins explained that individuals with type 5 diabetes typically require very small amounts of insulin or oral medication, as standard insulin doses can dangerously lower blood sugar and lead to severe complications, even death. She first noticed these treatment failures while treating young patients in Africa years ago. Currently, the American Diabetes Association (ADA) recognizes type 1, type 2, and gestational diabetes, as well as other types that are caused by specific conditions such as cystic fibrosis, pancreatic disease, organ transplant, steroid therapy, or genetic factors. Other medical organizations acknowledge additional forms of diabetes, such as type 3, which links insulin resistance to Alzheimer's disease, and type 4, which is age-related and found in lean, older adults. Despite advances in diabetes classification, there is no specific blood test to diagnose type 5 diabetes. Dr. Hawkins explained that the diagnosis is largely based on assessing the clinical picture, particularly the patient's history of childhood malnutrition. While malnutrition is the primary factor defining type 5 diabetes, Dr. Hawkins believes that awareness of this condition may also benefit individuals in higher-income countries who experience significant weight loss, such as those who undergo bariatric surgery or use GLP-1 medications. Concerns about this issue were raised by colleagues in Japan, who observed young women intentionally starving themselves and displaying a clinical profile similar to that of individuals with type 5 diabetes. However, Dr. Hawkins emphasized that more research is needed to understand whether extreme weight loss can actually lead to type 5 diabetes. Significant weight loss can reduce muscle mass, which, in turn, affects how the body processes glucose. As skeletal muscle is the body's largest insulin-sensitive tissue and accounts for much of its glucose uptake, losing muscle mass can result in insulin resistance—a condition where cells do not properly respond to insulin, leading to elevated blood sugar levels. While the American Diabetes Association has not yet classified type 5 diabetes, experts believe that the delay is likely due to the time required for internal review and consensus within the organization. Dr. Hawkins anticipates that the ADA will formally address the condition soon. Dr. Rozalina McCoy, an associate professor of medicine at the University of Maryland School of Medicine, suggested that there may already be cases of type 5 diabetes in the US that have gone unrecognized by healthcare providers. "It is important to consider this unique type of diabetes and treat it carefully, not only in those who have a childhood history of malnutrition, but also in those who have lost significant weight or are malnourished for other reasons, such as an eating disorder or weight loss treatment, either surgical or medical," McCoy said. As more attention is brought to type 5 diabetes, healthcare providers are urged to recognize and properly treat this condition, especially for individuals with a history of childhood malnutrition or significant weight loss.

Kuwait Health Ministry sets prices for 69 new medicines in private pharmacies
Kuwait Health Ministry sets prices for 69 new medicines in private pharmacies

Arab Times

time13-05-2025

  • Arab Times

Kuwait Health Ministry sets prices for 69 new medicines in private pharmacies

KUWAIT CITY, May 13: Minister of Health Dr. Ahmad Al-Awadhi on Monday approved Ministerial Resolution No. 93 of 2025, which sets the prices for 69 new medicines and pharmaceutical preparations in private sector pharmacies. The decision is part of ongoing efforts to ensure treatment safety and quality while balancing economic efficiency with high standards of healthcare. In a press statement, the Ministry of Health said the resolution aligns with its broader strategy to review and reduce medicine prices, aiming to make them among the lowest in the region. The move is based on recommendations from the Drug Pricing Committee and is intended to strengthen continuous monitoring of the pharmaceutical market, regulate prices, and ease the financial burden on patients — without compromising the quality and effectiveness of treatments. The decision also complements Ministerial Resolution No. 74 of 2023. The Ministry stated that the approved list covers a wide range of drug categories, including treatments for cancers such as leukemia, diabetes, high blood pressure, high cholesterol, anticoagulants, antidepressants, antiepileptics, antibiotics, antifungals, antivirals, asthma, osteoporosis, thyroid disorders, skin conditions, Alzheimer's and dementia, obesity, and migraines. The Ministry reaffirmed its ongoing commitment to ensuring equitable access to essential medications, reducing patients' financial strain, and strengthening a comprehensive and sustainable healthcare system in Kuwait. It is worth noting that last week, the Ministry approved a 30 percent price reduction for tirzepatide injections, a medication used for diabetes and weight management. In addition, the Ministry approved the prices of 146 medications in March 2025, reduced the prices of more than 200 medications in July 2024, and approved pricing for 228 pharmaceutical products in May 2024.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store